摘要:
Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译:用于治疗或预防心律失常的方法,组合物,给药方案和给药途径。 在这些方法中,可以通过向有需要的受试者施用离子通道调节化合物来减少或消除心律失常(例如房颤,心房扑动,早期去极化和QT间期延长)。 离子通道调节化合物可以是环烷基胺醚化合物,特别是环己胺醚化合物。 还描述了诱导早期后极化,延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。
摘要:
Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译:用于治疗或预防心律失常的方法,组合物,给药方案和给药途径。 在这些方法中,可以通过向有需要的受试者施用离子通道调节化合物来减少或消除早期后消极和延长QT间期。 离子通道调节化合物可以是环烷基胺醚化合物,特别是环己胺醚化合物。 还描述了诱导早期后极化,延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。
摘要:
Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译:用于治疗或预防心律失常的方法,组合物,给药方案和给药途径。 在这些方法中,可以通过向有需要的受试者施用离子通道调节化合物来减少或消除早期后消极和延长QT间期。 离子通道调节化合物可以是环烷基胺醚化合物,特别是环己胺醚化合物。 还描述了诱导早期后极化,延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。
摘要:
Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译:用于治疗或预防心律失常的方法,组合物,给药方案和给药途径。 在这些方法中,可以通过向有需要的受试者施用离子通道调节化合物来减少或消除心律失常(例如心房颤动,心房扑动,早期后极化和QT间期延长)。 离子通道调节化合物可以是环烷基胺醚化合物,特别是环己胺醚化合物。 还描述了诱导早期后极化,延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。
摘要:
Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.
摘要翻译:用于治疗或预防心律失常的方法,组合物,给药方案和给药途径。 在这些方法中,可以通过向有需要的受试者施用离子通道调节化合物来减少或消除心律失常(例如房颤,心房扑动,早期去极化和QT间期延长)。 离子通道调节化合物可以是环烷基胺醚化合物,特别是环己胺醚化合物。 还描述了诱导早期后极化,延长QT间期和/或Torsades de Pointes的离子通道调节化合物和药物的组合物。
摘要:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
摘要:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
摘要:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
摘要:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
摘要:
Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.